GANGLIOSIDES
============

Gangliosides are glycosphingolipids present in the outer leaflet of the plasma membranes, where significantly contribute to the surface properties of cells ([@B141]). These glycolipids are involved in various cellular functions, including signal transduction ([@B17]; [@B53]), regulation of cell proliferation and differentiation ([@B57]; [@B133]; [@B32]; [@B163]), cell--cell recognition ([@B48]), adhesion ([@B37]), and cell death ([@B42],[@B43]; [@B87]; [@B28]). Gangliosides function as the Ca^2+^ binding co-factor in synaptic transmission ([@B145]), and as the co-factor of membrane adenylate cyclase ([@B120]). Furthermore, they interact with, or are the receptors of different bioactive molecules, such as bacterial toxins ([@B139],[@B140]; [@B150]; [@B73],[@B71]; [@B82]; [@B96]), glycoprotein hormones ([@B97],[@B98]; [@B111]; [@B72]), type 1 interferon ([@B13]; [@B154]; [@B5]), fibronectin ([@B88]), lymphokines ([@B64]; [@B108]; [@B125]), and serotonin ([@B161]).

The processes accompanying malignant transformation, like oxidative stress, hypoxia, and angiogenesis, as well as the metastasis formation, induce the expression on cell membranes of potential targets for cancer immunotherapy. It has been widely documented that the expression patterns of membrane gangliosides suffer quantitative and qualitative changes during neoplastic transformations ([@B16]; [@B65]; [@B49]; [@B85]; [@B124]). Normal melanocytes express predominantly GM3, while GD3 increases when these cells suffer an oncogenic process ([@B126]). GD3 plays a role in the regulation of cell growth and the induction of angiogenesis by the tumor cells ([@B59]; [@B164]; [@B52]). Melanoma GD3 carries a ceramide portion with a long chain fatty acid, in contrast with the GD3 expressed in the normal tissues that carries a shorter chain fatty acid ([@B114]). Fucosyl GM1 is a unique structure that is found in small cell lung cancers (SCLC) with a very limited expression in normal tissues ([@B90]; [@B148]). GD2 is highly expressed on neuro-ectodermal tumors ([@B60]) and in sarcomas ([@B81]). This ganglioside is also a cancer stem cells marker and promotes tumorigenesis ([@B8]).

A very interesting case is the one of *N*-glycolylated (NeuGc) gangliosides, since these glycolipids are not naturally expressed in humans due to a genetic deletion in the gene that codes the CMP-*N*-acetyl hydroxylase, enzyme that catalyzes the conversion of *N*-acetyl to *N*-glycolyl sialic acid ([@B75]; [@B76]; [@B116]). However, both direct and indirect studies have indicated that NeuGc is overexpressed in several human tumors ([@B44]; [@B83]; [@B104]; [@B103]). The most accepted theory for this phenomenon is the incorporation of NeuGc from dietary sources. Free sialic acids from the medium can be taken up into cells via pinocytosis. The content of the resulting pinocytotic vesicles and endosomes would eventually be delivered to the lysosome, where a sialic acid transporter then delivers the molecules into the cytosol ([@B6]). Also endogenous synthesis from glycolyl-CoA is a possibility ([@B103]). The explanation for the differential expression of these antigens (Ag) in human normal and tumor tissues is that the rapidly growing tumor tissues might be more efficient at scavenging NeuGc. Furthermore, hypoxia induces the expression of sialin, a sialic acid transporter on tumor cells, and enhances the incorporation of the non-human sialic acid from the external milieu ([@B162]).

The gangliosides are not only attractive targets due to their over-expression on tumor cells membranes but also because of their importance for tumor biology. The metastatic capacity of the cells is strongly affected by the gangliosides expressed on the cell membranes: disialogangliosides GD2 and GD3 participate in the anchoring of the melanoma and neuroblastoma metastatic cells to the extracellular matrix proteins ([@B37]; [@B52]). Comparing the ganglioside pattern expressed by the primary tumor or the metastatic cells of a melanoma patient, gangliosides expression was higher in the last ones, especially GD1. There were also abundant *O*-acetylation of GM2, GD3, and GD2, which were absent in the primary tumor. GM2 is also strongly expressed in prostate metastasis ([@B166]), where is found in the areas of tumor cell-to-tumor cell contact indicating a role in cellular interactions and adhesion ([@B52]).

Furthermore, gangliosides actively shed from tumors are inserted into the plasmatic membrane of surrounding cells, affecting the function of lymphocytes ([@B106]; [@B100]; [@B160]; [@B92]; [@B55]), monocytes ([@B93]), natural killer cells ([@B45]), and antigen-presenting cells ([@B18]; [@B12]). Gangliosides have been found to shift the cytokine profile from Th1 toward the Th2 in affected cells ([@B31]). Negative modulation of CD4 molecule on T lymphocytes has been described for both the *N*-acetylated ([@B142]) and the *N*-glycolylated variants ([@B41]) of GM3 ganglioside. Gangliosides have been reported to block the nuclear translocation of NF-κB in human monocytes and dendritic cells ([@B18]). GD3, isolated from the polar lipid fraction of ovarian cancer-associated ascites, was shown to be an inhibitory factor that prevents innate immune activation of natural killer T cells ([@B158]). GM2 inhibits immunoglobulin production by B cells ([@B86]). In this way tumor released gangliosides reinforce tumor evasion by blocking the immunological surveillance.

Despite the fact that gangliosides are poorly immunogenic, due to their self and glycolipidic nature, several reports show the presence of naturally occurring antibodies, not only in cancer patients, but also in healthy individuals, suggesting that anti-ganglioside reactivity is fixed in the natural antibodies repertoire.

NATURALLY OCCURRING ANTI-GANGLIOSIDE ANTIBODIES
===============================================

Natural antibodies are considered humoral mediators of innate immunity and recognize antigens highly conserved throughout evolution ([@B27]). It has been proposed that natural auto-antibodies and auto-reactive T cells in healthy individuals may be directed to a specific and limited set of self-molecules; this selective autoimmunity has been termed the immunological homunculus ([@B24]). Due to the limited number of mutations in the genes encoding the variable region of these antibodies, the repertoire of these immunoglobulins is highly conserved within species ([@B27]). Several authors have described their capacity to bind foreign antigens but also self and altered self-antigens, which may be or not of protein nature ([@B24]). These antibodies recognize epitopes associated with pathogens, such as phosphorylcholine of Gram-positive bacteria, lipopolysaccharide (LPS) of Gram-negative bacteria, and various molecules expressed by parasites ([@B115]; [@B10]). For this reason they are considered as a first, quick anti-infection barrier that helps to guarantee the survival since the very beginning of the organisms' life. Among their targets have also been identified intracellular molecules, such as some nuclear (e.g., histones) and cytoskeleton (e.g., actin) proteins ([@B30]) and single-stranded DNA ([@B136]). They also recognize peptides (e.g., amyloid beta peptide), plasma membrane glycoproteins (e.g., CD90; [@B136]), oxidized lipids (e.g., phosphatidylcholine), and antigens expressed by apoptotic cells (Annexin IV; [@B40]; [@B9]). Mounting evidence suggest that natural IgM antibodies, through this self-reactivity might contribute to critical innate immune functions involved in the maintenance of tissue homeostasis, like the clearance of apoptotic cells ([@B40]), reduction of atherosclerotic lesions ([@B58]; [@B23]), and the reinforcement of mechanisms involved in the protection from the development of autoimmune disease ([@B159]; [@B35],[@B36]; [@B138]; [@B80]; [@B143]).

Recently it has been described the existence of auto-antibodies against tumor-associated antigens, which can arise in the patients even before the symptoms become evident and that can be detected also in healthy donors ([@B165]; [@B144]; [@B33]). Some of these IgM isotype, germline antibodies have been isolated from cancer patients and have proved to be able not only to recognize tumor cells, but also to kill them by different mechanisms ([@B14]; [@B61]; [@B77]; [@B155], [@B156]; [@B101]). Many of the detected anti-tumor antibodies bind to carbohydrate repeated motifs, including sequences of sugars contained in gangliosides ([@B102]; [@B27]).

Naturally occurring antibodies reacting with tumor-associated gangliosides have been detected in cancer patients but also in healthy donors. Antibodies against GM2 and GD2 were detected in the sera of both melanoma patients and healthy individuals ([@B157]; [@B146]). Other authors have reported the existence in healthy donors of naturally occurring antibodies with reactivity against gangliosides like GM1, GD1a, GD1b, and GT1b ([@B109]; [@B128]; [@B95]). Silent auto-reactive B clones have also been identified in cancer patients, from which human monoclonal antibodies (mAb) against gangliosides were generated. The mAb GMA1 reacted with the gangliosides GD3, GM3, and GD2 from melanoma and neuroblastoma cell lines and not normal tissues ([@B110]). The human monoclonal IgM antibody 7c11.e8, also generated by fusing lymph node cells isolated from a surgical specimen of malignant melanoma reacted with GM4, GM3, and GD3. In the presence of human serum the antibody initiated a strong lysis of melanoma tumor cells in complement-dependent cellular cytotoxicity (CDCC) assays ([@B1]).

The presence of naturally occurring antibodies that recognize NeuGc acid present in tumor-associated glycoconjugates has also been described. It has been shown that normal human serum contains high levels of NeuGc-specific antibodies, which attract complement molecules to the surface of leukemic cells expressing NeuGc, but not other normal cells ([@B167]; [@B147]; [@B113]; [@B119]). [@B127], examining the sera of healthy volunteers between the ages of 18 and 90, reported that anti-ganglioside antibodies occurred naturally and that their levels decline after 50 years, which could be relevant since the cancer incidence increases with age.

Anti-ganglioside antibodies have shown to have anti-tumor cytotoxic capacities. It has been reported the ability of a murine anti-GM2 to induce apoptosis through caspase activation in lymphoma, melanoma, and lung cancer cells expressing the antigen ([@B130]). The binding of an anti-GD2 antibody to the ganglioside expressed in lung cancer cells induced apoptosis by the reduction in the levels of phosphorylation of FAK and activation of mitogen-activated kinase p38. Immunoprecipitation experiments showed a physical association of GD2 with integrins, which were associated with FAK inside the membrane. Antibody binding to ganglioside caused conformational changes in this complex, inducing the transmission of intracellular signals that mediated the apoptosis ([@B2]). It has been also proved that anti-GD2 antibodies of healthy donors have cytotoxic capacity against neuroblastoma cells ([@B117]).

The capacity of the mAb 14F7, a murine IgG highly specific for NeuGcGM3, to induce oncotic cell death to tumor cells expressing this antigen has been reported. This antibody induced a tumor cell death that was accompanied by cellular swelling, membrane lesion formation, and cytoskeleton activation ([@B20]; [@B132]). Another antibody specific for *N*-glycolylated gangliosides is P3 mAb. This is an IgM, germline encoded that is able to induce complement-mediated cytotoxicity to NeuGc expressing tumor cells ([@B152]; [@B19]). It has been reported that naturally occurring anti-NeuGc in healthy humans were able to kill human leukemic cells that were exogenously fed with NeuGc by a complement-mediated mechanism ([@B113]).

These evidences suggest that the evolution has fixed an innate immunity against gangliosides in the natural antibodies repertoire, which could play an important role for tumor immune surveillance. Since the natural antibodies secreting B cells arise in the neonatal period, they could be connected and regulated by anti-Id interactions, according to Jerne's idiotypic network theory.

THE IDIOTYPIC NETWORK THEORY
============================

In 1974, Neils Jerne published the Idiotypic Network theory, which gave a different view of the immune system organization and the recognition of the "self." According to classical clonal selection theory, the immune system was "antigen driven" and in the absence of an external antigen challenge the system should be passively inactive. In contrast, according to the network theory, the immune system consists of lymphocyte clones which are stimulated and regulated by the immunoglobulins produced by other clones within the network. Since a huge diversity of idiotypes (Id) is generated by random somatic rearrangements of genes, idiotype's complementary structures can be found not only on antigens but also on antibodies of different idiotypes. In Jerne's own words "the immune system of a single animal, after producing specific antibodies to an antigen, continues to produce antibodies to the idiotopes of the antibodies which it has itself made. The latter anti-Id antibodies likewise display new idiotypic profiles, and the immune system turns out to represent a network of idiotypic interactions" ([@B78], [@B79]).

This phenomena was extensively proved firstly by Kunkel and Oudin, who showed that ordinary antibody molecules that arise in an immunized animal are antigenic and induce the formation of specific anti-antibodies ([@B91]; [@B118]). Later experiments further demonstrated that the recognition of self-idiotopes by B or T cells is an active physiological process controlling the suppression or expansion of the immune response ([@B47]; [@B21]; [@B149]; [@B15]).

This immune network is established in the neonatal period, thus this theory predicts that the immune systems has an autonomous activity, manifested by the presence of activated lymphocytes and antibody secretion, before any external immunization. This prediction was confirmed by studies on "antigen-free" animals, which contain in their spleen and peritoneal cavity activated B cells that secret IgM antibodies and T lymphocytes that perform as effector cells, help or suppress the antibody production ([@B74]; [@B121]).

Thus, a network of idiotypically interacting immune cells is formed, that has a dynamic equilibrium between the idiotypes, anti-Id, and the normal self-constituents of our body, influencing the shaping of the B- and T cell repertoires, and controlling auto-reactive clones.

In the 1980s, there was an interesting debate between the proponents of the network paradigm and those of the clonal selection theory and several experiments were performed that provided evidences about both ideas ([@B25], [@B26]; [@B94]; [@B22]; [@B11]).

The establishment of collections of antibody-producing hybridomas, derived from normal, unimmunized mice at different stages of ontogeny, provided proof for the existence of idiotypic connectivity ([@B66]). Matrices of idiotypic complementarities were established, that allowed to estimate the degree of connectivity within different B cell populations ([@B66],[@B67], [@B68],[@B69],[@B70]; [@B84]). High levels of connectivity were observed within collections of fetal or neonatal origin ([@B67]). However, within collections from the adult lymphocyte population the degree of connectivity was 10- to 100-fold lower ([@B70]). These experiments suggested that high idiotypic connectivity is not an intrinsic property of any collection of IgM antibodies, but a distinctive property of part of the perinatal antibody repertoire.

Then, Varela and Coutinho formulated the concept of second-generation immune networks ([@B29]; [@B151]), which tried to combine the two competing paradigms. They adopted the view that the immune system is formed by two compartments of B and T lymphocytes: a majority of small resting cells constituting 80--85% of the total population and a set of large activated cells making up the other 15--20% ([@B122], [@B121]), this last being the predominant in the neonatal period. The specific response to a foreign antigen would be mainly caused by the activation of resting lymphocyte clones, which are only poorly connected to the network, thus forming the peripheral part of the system. The fraction of highly connected cells forms the actual network, a compartment of naturally activated lymphocytes. The immune network includes, in addition to V-regions, all other molecules of the somatic self. This pool of connected cells may be responsible for maintenance of normal network dynamics and prevention of auto-aggression.

The idiotypic network hypothesis predicts that due to the huge diversity of immunoglobulin variable regions, and since each antibody will bind its nominal antigen and also other immunoglobulins, within the immune network the universe of external antigens is mimicked by idiotypes. According to this concept, immunization with a given antigen will generate the production of antibodies against this antigen termed Ab1. This Ab1 can generate a series of anti-Id antibodies against Ab1 termed Ab2. The particular anti-Ids which fit into the antigen binding site of the Ab1, can induce a specific immune responses against the nominal antigen. Then, a practical consequence of the idiotypic network theory was that the idiotopes could be used to mimic any existing antigen and used as surrogate antigens. Immunization with Ab2 can lead to the generation of anti-anti-Id antibodies (Ab3) that recognize the corresponding original antigen identified by the Ab1 (**Figure [1](#F1){ref-type="fig"}**). Several such Ab2 have been used to trigger the immune system to induce specific and protective immunity against tumor antigens ([@B107]; [@B79]; [@B99]; [@B129]).

![**According to the idiotypic network theory, idiotype's complementary structures can be found not only on antigens but also on antibodies of different idiotypes**. The immune system after producing specific antibodies to an antigen (Ab1), continues to produce antibodies to the Ab1 idiotopes (Ab2). The particular Ab2 which fit into the antigen binding site of the Ab1, can induce a specific immune responses against the nominal antigen. Thus, the idiotopes could be used as surrogates of any existing antigen. Immunization with Ab2 can lead to the generation of anti-anti-Id antibodies (Ab3) that recognize the corresponding original antigen identified by the Ab1. Several Ab2 have been used to induce specific and protective immunity against tumor antigens.](fonc-02-00170-g001){#F1}

Although Jerne, in his original network hypothesis, and later Coutinho with the second generation networks outlined the importance of naturally occurring idiotypic complementaries, must of the studies using anti-Id as vaccines are focus on the great mimetic capacity of idiotypes, no in activating network related properties, like immune regulation and natural immune surveillance. Beyond the functional mimetic capacity, those anti-Id antibodies related with antigens connected and regulated though networks due to their importance for organisms' homeostasis, could be able to activate natural antibodies secreting B cells. Their antigens, especially self-antigens, could be the suited ones to get targeted through the idiotypic vaccination. This could be the case of gangliosides.

ANTI-GANGLIOSIDE IDIOTYPIC VACCINES
===================================

Anti-idiotype antibodies that mimic ganglioside have been utilized as active specific immunotherapy in patients with different tumors. [@B34] generated in syngeneic mice the anti-Id antibody BEC2 against the anti-GD3 mAb R24. In studies in rabbits this antibody demonstrated its ability to mimic GD3, inducing a specific antibody response of IgG and IgM isotypes. In clinical trials in melanoma patients treated by surgery and with high risk of recurrence ([@B105]) and in patients with SCLC with limited disease ([@B56]) BEC2 demonstrated to be immunogenic and to induce anti-anti-Id response when administered with the adjuvant BCG. However, it induced specific anti-GD3 antibodies only in a low percentage of patients ([@B34]; [@B105]; [@B56]). The conjugation of BEC 2 to KLH did not increase but reduced the magnitude and frequency of the anti-GD3 response. When anti-GD3 antibodies were induced, they were detected only by ELISA, not by TLC immunostaining ([@B131]) or by flow cytometry against GD3-positive melanoma cell lines, suggesting that these anti-GD3 antibodies had a relatively low avidity for cell surface GD3. A phase III trial with 515 patients with limited-disease SCLC after a major response to chemotherapy and chest radiation was performed with BEC2/BCG. This trial failed to show any survival advantage for vaccinated patients. Only one-third of the patients elicited an anti-GD3 response. Among vaccinated patients, a trend toward prolonged survival was observed in those who developed the humoral response (*P* = 0.085), so that it was suggested that the induction of higher titers of antibodies in a larger proportion of patients could make an impact on median survival ([@B54]).

Another trial that targeted a ganglioside, utilized a vaccine composed of an anti-Id mimicking GD2 injected with the adjuvant QS21, a preparation called TriGem. The anti-Id mAb, called 1A7 is a functional mimic of a specific epitope in the ganglioside GD2. In preclinical studies in mice, rabbits, and monkeys the immunization with 1A7 antibody induced a specific IgG response against the ganglioside, capable of causing the lysis of GD2-positive cells on ADCC assays ([@B137]).

[@B51] initiated a clinical trial in patients with advanced melanoma, which were given anti-Id mAb 1A7 with the adjuvant QS21. All sera showed an anti-anti-Id response mainly of the IgG1 isotype. The purified Ab3 from all patients inhibited the binding of the Ab1 to a GD2-positive cell line and to purified GD2. In addition, sera specifically reacted with tumor cells expressing GD2 and were positive in ADCC studies. One patient had a complete clinical response and 6 patients, of a total of 12 enrolled in the trial were stable from 9 to 23 months. In a similar trial, 47 patients with advanced melanoma received 1, 2, 4, or 8 mg doses of TriGem. Hyperimmune sera from 40 of the 47 patients showed an anti-anti-Id response of IgG isotype that specifically bound purified GD2. One patient had a complete response that persisted at 24 months, and 12 patients were stable from 14 to 37 months (median, 18 months). These results showed that this vaccine had minimal toxicity, induced a strong response against GD2 and seemed to have a favorable impact on the reduc-tion of disease progression and survival of patients ([@B51], [@B50]).

In 2003, Basak and colleagues generated Ab2 against the anti-GD2 mAb ME361. These Ab2s induced a specific DTH response in mice against melanoma cell lines that express this ganglioside. Furthermore, these antibodies were able to induce proliferative responses in cells from a melanoma patient confronted with human melanoma cells expressing GD2 *in vitro*, demonstrating the ability of these antibodies to induce cellular responses against carbohydrate antigens ([@B7]).

Several evidences have shown that tumor antigen-specific antibodies Ab1, used in preclinical experiments or for diagnostic and/or therapeutic purposes, may contribute to anti-tumor effects by triggering the idiotypic cascade and inducing a tumor antigen-specific immune response. The triggering of the idiotypic cascade has been reported to be associated with a favorable clinical response to antibody-based therapy in patients with neuroblastoma, colorectal carcinoma, ovarian carcinoma, and non-Hodgkin lymphoma ([@B89]; [@B134]; [@B38], [@B39]; [@B135]). GD2 ganglioside-specific antibodies have been induced in patients with neuroblastoma treated with anti-GD2 ganglioside antibodies.

Treatment with the anti-GD2 monoclonal antibody 3F8 (Ab1) at the time of remission prolonged the survival of children with stage 4 neuroblastoma. Among 34 patients treated with this antibody at the end of chemotherapy 14 were alive, and 13 (1.8--7.4 years at diagnosis) were progression-free (53--143 months from the initiation of 3F8 treatment) without further systemic therapy at the moment of the report. This long-term progression-free survival and survival correlated significantly with the induction of Ab3 anti-GD2 response ([@B39]). These results reinforce the importance of GD2 as a tumor target, and the connectivity capacity of anti-ganglioside antibodies.

Our group has developed a vaccine preparation featuring a murine anti-Id mAb related to the NeuGc-containing ganglioside antigen model. This Ab2, named 1E10 ([@B153]), was generated from the immunization of BALB/c mice with P3, an idiotypic antibody (Ab1) that recognizes NeuGc-containing gangliosides, sulfated glycolipids, and antigens present in different human tumors including those from the lung. This Ab1 is highly immunogenic in the syngeneic model, inducing an anti-Id response in the absence of adjuvant or carrier protein. Furthermore, the Ab1 P3 was able to activate NeuGcGM3 related idiotypic cascade, since antibodies against NeuGcGM3 (Ab3, Ab1 like) were detected in chickens immunized with this Ab1. The detection of Abs with this specificity in animals immunized with an Ab1 suggested that the elicited Ab2s behaved as a ganglioside surrogate inducing a specific Ab3 response against this antigen.

Preclinical data published by our group suggest that P3 and 1E10 mAb could be able to activate idiotypic networks, involving both B and T cells. Lymph node cells from BALB/c mice immunized with P3 mAb proliferated *in vitro*, in a dose-dependent manner, not only in response to P3 mAb but also to 1E10 mAb, suggesting the existence of a naturally occurring B/T cell idiotypic network ([@B123]). Phase I clinical trials have proven the safety and immunogenicity of 1E10 Id vaccination in melanoma, breast, and lung cancer patients ([@B3], [@B4]; [@B46]; [@B112]; [@B63]). In all the cases, 1E10 idiotype proved to be immunodominant, since the induced anti-anti-Id response was significantly higher than the anti-isotypic response. Similar results were obtained when monkeys and chickens were immunized with 1E10 mAb ([@B62]), suggesting that 1E10 mAb Id immunodominance is not a species-depending property. High titer antibody responses to NeuGc-containing gangliosides were measured in the sera of cancer patients and were confirmed by TLC immunostaining. Interestingly, a fraction of non-suppressible anti-NeuGc-containing ganglioside Abs was demonstrated after the adsorption of the patients' sera with 1E10 mAb, suggesting that 1E10 Id vaccination was activating natural anti-NeuGcGM3 responses ([@B63]). The antibodies that recognize both 1E10 and the ganglioside (Id^+^Ag^+^) and the ones that recognize the ganglioside but not the immunizing Ab3 (Id^-^Ag^+^), recognized and induced the death of tumor cells expressing NeuGcGM3 by an oncotic necrosis mechanism. Those patients who developed IgG and/or IgM Abs against NeuGcGM3 showed a longer survival time. We hypothesize that 1E10 Id vaccination could be activating an existing idiotypic cascade related with *N*-glycolylated gangliosides, which would amplify the antigen-specific immune response to a tumor-associated neo-self antigens. This therapeutic concept goes beyond the classical concept of antigen mimicry. A randomized, double blind phase II clinical trial is ongoing to evaluate the clinical effect of 1E10 mAb vaccine in NSCLC patients and to define the value of the Abs induced by the anti-Id treatment as real predictors of clinical outcome. For a chronological representation of the principal milestones in the development of anti-Id vaccines against tumor expressed gangliosides see **Figure [2](#F2){ref-type="fig"}**.

![**Timeline of highlight milestones in the development of anti-idiotypic vaccination against tumor gangliosides**.](fonc-02-00170-g002){#F2}

CONCLUDING REMARKS
==================

At present, most of the anti-Id vaccine approaches are based and study the mimetic capacity of the anti-Id antibodies, without searching for their immunoregulatory or natural anti-tumor potential. The use of anti-Id antibodies as immunogens could offer the possibility not only to generate Ab3 antibodies against their own idiotopes, but also to inducing a cascade of Id--anti-Id interactions leading to an amplified and long lasting immune response against the nominal antigen. This immunization could also involve T cells in the response against glycolipidic antigens. The expansion of natural antibodies repertoire by idiotypic vaccination could even participate in the lysis of tumor cells by the activation of evolutionarily fixed anti-tumor mechanisms. A naturally occurring antibody response against ganglioside, which has shown to carry anti-tumor properties, exists in healthy individuals and cancer patients. The idiotypic vaccination could be an optimum way to activate the idiotypic B and T cell cascades involving the natural responses against these antigens.
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